Literature DB >> 18231109

High birth weight as an important risk factor for infant leukemia.

S Koifman1, M S Pombo-de-Oliveira.   

Abstract

In this paper, we compared the birth weight distribution among 201 infant leukaemia (IL) cases with that of 440 noncancer controls enrolled in Brazil in 1999-2005. Compared with the general population and the stratum 2500-2999 g as reference, IL cases weighing 3000-3999 g presented an odds ratio (OR) of 1.68 (95% CI: 1.03-2.76), and those of 4000 g or more, an OR of 2.28 (95% CI: 1.08-4.75), P trend<0.01. Using hospital-based controls, the OR for 4000 g or more, compared to 2500-2999 g, was 1.30 (95% CI: 1.02-1.43) after adjusting for confounders (gender, income, maternal age, pesticide and hormonal exposure during pregnancy). The results suggest that high birth weight is associated with increased risk of IL.

Entities:  

Mesh:

Year:  2008        PMID: 18231109      PMCID: PMC2243143          DOI: 10.1038/sj.bjc.6604202

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


The positive association between birth weight and increased risk of childhood leukaemia has been reported in industrialised countries (Westergaard ; Hjalgrim ). Acute lymphoblastic leukaemia (ALL) or acute myeloblastic leukaemia (AML) affecting infants (under 12 months), which have been little studied, often contain a chromosome break following the recombination of the MLL gene with other genes (Felix and Lange, 1999). It has been hypothesised that malignant clones, which will promote acute leukaemias in early infancy would result from maternal exposures to such environmental agents as dietary items and chemicals inhibitors of DNA topoisomerase II activity (Ross ; Alexander ). In a recent molecular case–control study in Brazil of infant leukaemia (IL) with MLL gene rearrangements, a strong and significant association between maternal use of hormones during pregnancy and IL was observed (Pombo-de-Oliveira ). Also of relevance, oestriol, progesterone and prolactin measured during pregnancy are reported as positively associated with birth weight and cancer risk in offspring (Mucci ; Nagata ). We have therefore examined IL risk in relation to birth weight using an existing database constructed by the Brazilian Collaborative Study Group of Infant Acute Leukaemia (BCSGIAL).

MATERIALS AND METHODS

The BCSGIAL is a cooperative study group in different states of Brazil running a hospital-based case–control study to evaluate associations with IL maternal exposures to environmental risk factors during pregnancy. Details regarding case definition, control selection, exclusion criteria and data collection have been published previously (Emerenciano ; Pombo-de-Oliveira ). In this report, IL cases were included whenever birth weight data were available. Controls were children, matched for age strata and gender, with life-threatening conditions in the same hospitals as the cases, excluding malignancy. Data on birth weight were obtained from the health-care cards, regulated by the Brazilian National Health System. Birth weight data from IL cases were either compared with hospital-based controls, or with population-based data relating to all births in the general population of Brazil in the year 2000, and consolidated by the Brazilian National Health System (Ministério da Saúde, 2007). We ascertained birth weight by gender, leukaemia type (ALL and AML) and MLL status. Crude and adjusted odds ratios (ORs), and their 95% confidence intervals, were ascertained for the birth weight strata (2500 g or less; 2500–2999 g; 3000–3499 g; 3500–3999 g; and 4000 g or more) adjusted for selected confounders (gender, income, maternal age, hormonal intake and pesticide exposure during pregnancy). The available national data on birth weight merged 3000–3499 g and 3500–3999 g strata, and this was followed with IL birth weight to allow the relevant comparisons. Statistical analyses were performed using unconditional logistic regression models, as described elsewhere (Pombo-de-Oliveira ) and using the packages SSPS, version 13.5 (SPSS, Chicago, IL, USA). All collaborating institutions approved the BCSGIAL Study, and written consent was obtained for diagnostics procedures and for interviews with the mothers.

RESULTS

A total of 641 subjects, 201 cases (148 ALL and 53 AML) and 440 controls, stratified by age at diagnosis (0–12 versus 13–21 months), were enrolled in 1999–2005. The numbers of the main clinical and laboratory data were same as described previously (Emerenciano ), but eight AML cases were excluded due to lack of birth weight records. Eight cases, which were misclassified in the previous report as biphenotypic leukaemia with aberrant phenotype, were then categorized as ALL in the present analysis. Low birth weight (<2500 g) was found in 16 (8.0%) cases and in 74 (16.8%) controls. The comparison between IL and controls birth weight distributions showed that both ALL and AML weighed on average 3488 g at birth, compared with 3226 g among controls (P=0.0002); median birth weights were 3310 and 3226 g for ALL and AML, respectively. Children with ALL had slightly higher birth weights than AML, while male infants were slightly heavier than female infants. The birth weight for male IL infants was 3349.2 g (s.d.=49.6), with 95% CI: 3250.9–3447.5; for female IL infants, the birth weight was 3262.8 g (s.d.=48.8), 95% CI: 3166.0–3359.7. Further stratification by age revealed minimal differences between the strata before or after 12 months of age at diagnosis of IL (data not shown). It should, however, be remarked that MLL status in the current study was unknown for a larger proportion of children with low birth weight. Data were stratified according to MLL gene status (positive, negative and unknown). Mean birth weight in MLL+ve cases (n=68) was 3340 g (s.d.=64.85), while in MLL−ve cases (n=80), it was 3310 g (s.d.=51.2); the medians were 3310 and 3300 g, respectively. The magnitude of the association with birth weight IL was also explored in increasing weight strata (Tables 1 and 2). Compared to birth weights 2500–2999 g, higher weights showed increased ORs for either ALL or AML regardless of the control, population or being hospital-based. Compared with the general population, ALL cases weighing 3000–3999 g showed an OR of 1.68 (95% CI: 1.03–2.76), and those weighing 4000 g or more, an OR of 2.28(95% CI: 1.08–4.75, P<0.01, Table 1). The cases that were MLL+ve showed a higher birth weight than MLL−ve cases at ages 12–21 months, and an inverse relationship in the first year of life was observed (figures available online).
Table 1

Birth weight distribution, ALL, AML, MLL status (1999–2005) and all births in Brazil (general population), 2000

Birth weight General population IL
ALL
AML
MLL +ve
MLL −ve
(in g) (all births) n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI)
<2500243 835161.52 (0.80–2.89)111.50 (0.72–3.11)51.59 (0.46–5.16)61.56 (0.51–4.54)30.61 (0.14–2.26)
2500–2999696 925301.00211.0091.0011100141.00
3000–39992 036 9251431.63 (1.08–2.47)1031.68 (1.03–2.76)391.48 (0.64–3.28)431.34 (0.67–2.75)581.42 (0.77–2.66)
>3999189 476131.59 (0.79–3.17)a132.28 (1.08–4.75)b082.68 (0.99–7.15)c51.31 (0.41–3.89)d

ALL=acute lymphoblastic leukaemia; AML=acute myeloblastic leukaemia; CI=confidence interval; IL=infant leukaemia; OR=odds ratio.

χ2 for trend=4.60, P=0.03.

χ2 for trend=6.66, P<0.01.

χ2 for trend=3.56, P=0.059.

χ2 for trend=0.91, P=0.34.

Table 2

Birth weight distribution by weight strata, IL and hospital-based controls, Brazil, 1999–2005

   All IL
ALL
AML
Birth weight Hospital-based   Crude Adjusteda   Crude Adjusteda   Crude Adjusteda
(in g) controls n OR (95% CI) OR (95% CI) n OR (95% CI) OR (95% CI) n OR (95% CI) OR (95% CI)
<250074160.87 (0.42–1.79)0.88 (0.41–1.86)110.86 (0.36–1.99)0.99 (0.41–2.42)50.91 (0.25–3.12)0.74 (0.21–2.55)
2500–2999121301.001.00211.001.0091.001.00
3000–3499150812.18 (1.31–3.63)1.23 (1.04–1.46)572.19 (1.18–2.93)1.24 (1.02–1.50)242.15 (0.91–5.20)1.20 (0.91–1.58)
3500–399972623.47 (1.00–6.08)1.29 (1.12–1.48)463.68 (1.96–6.96)1.30 (1.11–1.52)152.80 (1.08–7.36)1.23 (0.98–1.55)b
>399923132.28 (0.96–5.37)1.20 (1.02–1.43)c133.26 (1.32–8.01)1.31 (1.09–1.57)d  

ALL=acute lymphoblastic leukaemia; AML=acute myeloblastic leukaemia; CI=confidence interval; IL=infant leukaemia; OR=odds ratio.

Adjusted for sex, income, maternal age, pesticide exposure and hormonal intake during pregnancy.

χ2 for trend=5.51, P=0.018.

χ2 for trend=16.70, P=0.00004.

χ2 for trend=18.14, P=0.00002.

DISCUSSION

Despite the many studies on childhood leukaemia and birth weight, few have focused on IL exclusively (Ross ; Yeazel ), which is in spite of the value of risk factors specifying the age group and the childhood leukaemia subtypes (Ma ). The main strength of our study is probably the almost complete ascertainment of IL in all Brazil except the North region, Amazon. In a population-based cohort, a positive linear relation was reported between birth weight, and childhood ALL and AML (Paltiel ; Mclaughlin ), more marked in AML among infants (hazard ratio=8.14, 95% CI: 1.8–38.9 at age 0–1 years), being particularly strong among female infants (P=0.001) (Paltiel ). Among the variables included in this study, including maternal origin, socioeconomic status, birth weight of sibling higher than 3500 g and family size, only birth weight retained borderline significance (Paltiel ). This association has been explored in the present study using different approaches, for IL ALL, AML and MLL status: according to a single weight cut-point, and also exploring the magnitude of association among subsequent birth weight strata. All approaches yielded results that suggested an association between high birth weight and IL. In our study, low birth weight was more common among controls (16.8%) than IL cases (8.0%), which may have estimates of the magnitude of the association with birth weight (Figure 1). Comparisons with the general population were therefore important to control for bias in our hospital-based controls. In this connection, three different OR estimates with birth weight were obtained with the general population, providing unbiased estimates but without adjusting confounders, crude ORs using hospital controls and adjusted ORs using hospital controls.
Figure 1

Birth weights (in g) strata distribution, IL cases, controls and the general population, Brazil.

Comparisons with the general population revealed an insignificantly increased trend in ORs between ALL and birth weight (Table 1) compared with children weighing 2500–2999 g at birth. Those weighing 3000–3999 g showed an OR of 1.69 (95% CI: 1.03–2.76), and those born with 4000 g or more, an OR of 2.28 (95% CI: 1.08–4.75), suggesting a dose–response effect (P<0.01). A quite similar trend with a borderline statistical significance was also observed for MLL+ve cases (Table 1; P=0.059). Birth weight strata of hospital controls suggested a dose–response effect for IL, and also for ALL and AML subtypes after adjusting for certain confounders. For AML, discordant results have been reported with birth weight (Ross ; Westergaard ; Yeazel ; Hjalgrim ). Despite no AML infants weighed more than 4000 g, suggestive dose–response trend was indeed observed. With respect to the biological mechanisms underlying birth weight and IL development, one of the factor is hormone intake during pregnancy to induce abortion to the index pregnancy (Ou ). In a previous report, we observed a high association between hormone intake during pregnancy and IL with an OR of 8.76, 95% CI: 2.85–26.93 (Pombo-de-Oliveira ). Women used oral contraceptive pills in the belief that they caused miscarriage, because abortion is illegal in Brazil. Although it could be hypothesised that the association with birth weight was partly due to such hormonal intake during the pregnancy, inducing an increase in birth weight. Although our results seem to point to an independent effect of birth weight, it has been suggested that rather than birth weight per se, the accelerated growth during pregnancy is the main process leading to IL (Milne ). On the other hand, the United Kingdom Childhood Cancer Study has reported that babies who developed leukaemia were heavier at birth (>4000 g, OR of 1.2, 95% CI: 1.0–1.4), as were their older siblings (>4000 g, OR of 1.4, 95% CI: 1.0–1.9) (Roman ). Other mechanisms suggested for the association with birth weight include the supposition that IL is initiated by aberrant gene fusions, mainly with MLL rearrangements (Ross ; Alexander ). Interactions between high birth weight, prenatal oestrogen exposure and leukaemia risks have also been suggested (Ross ; Baik ; Ross, 2006). An association has recently been reported between ALL and birth weight among MLL+ve cases, but not among MLL−ve ones (Spector ). In our study, a similar pattern was observed, with a borderline linear trend suggestive of a causal relationship. It has been suggested that insulin-like growth factor-1 (IGF-1) promotes a proliferative advantage to damaged cells (Ross ; Ross, 2006). The link between birth weight, steroid hormones in intrauterine life such as IGF-1 and cancer risk indicates that such hormones tend to increase the number of stem cells and, by extension, more proliferating immature cells are exposed to harmful events, and consequently become more susceptible to malignant transformation (Cavalieri ; Boyne ). Whether enhanced cell proliferation and genotoxic metabolites act jointly in an additive or synergistic fashion, resulting in expansion of clonal cells with gene fusion rearrangements, and clinical IL in high birth weight babies, warrants further investigation in experimental models.
  23 in total

1.  Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States).

Authors:  Lorelei A Mucci; Pagona Lagiou; Rulla M Tamimi; Chung-Cheng Hsieh; Hans-Olov Adami; Dimitrios Trichopoulos
Journal:  Cancer Causes Control       Date:  2003-05       Impact factor: 2.506

2.  Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group.

Authors:  J A Ross; J D Potter; G H Reaman; T W Pendergrass; L L Robison
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

3.  The relationship among circulating insulin-like growth factor (IGF)-I, IGF-binding proteins-1 and -2, and birth anthropometry: a prospective study.

Authors:  Michael S Boyne; Minerva Thame; Franklyn I Bennett; Clive Osmond; John P Miell; Terrence E Forrester
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

Review 4.  Big babies and infant leukemia: a role for insulin-like growth factor-1?

Authors:  J A Ross; J P Perentesis; L L Robison; S M Davies
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

5.  Evaluating the relationships among maternal reproductive history, birth characteristics, and infant leukemia: a report from the Children's Cancer Group.

Authors:  J A Ross; J D Potter; X O Shu; G H Reaman; B Lampkin; L L Robison
Journal:  Ann Epidemiol       Date:  1997-04       Impact factor: 3.797

6.  Birth characteristics, sibling patterns, and acute leukemia risk in childhood: a population-based cohort study.

Authors:  T Westergaard; P K Andersen; J B Pedersen; J H Olsen; M Frisch; H T Sørensen; J Wohlfahrt; M Melbye
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

7.  Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion.

Authors:  F E Alexander; S L Patheal; A Biondi; S Brandalise; M E Cabrera; L C Chan; Z Chen; G Cimino; J C Cordoba; L J Gu; H Hussein; E Ishii; A M Kamel; S Labra; I Q Magalhães; S Mizutani; E Petridou; M P de Oliveira; P Yuen; J L Wiemels; M F Greaves
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies.

Authors:  Lisa Lyngsie Hjalgrim; Tine Westergaard; Klaus Rostgaard; Kjeld Schmiegelow; Mads Melbye; Henrik Hjalgrim; Eric A Engels
Journal:  Am J Epidemiol       Date:  2003-10-15       Impact factor: 4.897

9.  Birth weight and other risk factors for acute leukemia in the Jerusalem Perinatal Study cohort.

Authors:  Ora Paltiel; Susan Harlap; Lisa Deutsch; Ariella Knaanie; Sausan Massalha; Efrat Tiram; Micha Barchana; Yehiel Friedlander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-06       Impact factor: 4.254

10.  Fetal growth and acute childhood leukemia: looking beyond birth weight.

Authors:  Elizabeth Milne; Crystal L Laurvick; Eve Blair; Carol Bower; Nicholas de Klerk
Journal:  Am J Epidemiol       Date:  2007-04-18       Impact factor: 4.897

View more
  7 in total

Review 1.  The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic?

Authors:  Frank A Simmen; Rosalia C M Simmen
Journal:  Eur J Cancer Prev       Date:  2011-11       Impact factor: 2.497

2.  Leukemia, non-Hodgkin's lymphoma, and Wilms tumor in childhood: the role of birth weight.

Authors:  Marina Rangel; Mônica Cypriano; Maria Lúcia de Martino Lee; Flávio Augusto Vercillo Luisi; Antonio Sérgio Petrilli; Maria Wany Louzada Strufaldi; Maria do Carmo Pinho Franco
Journal:  Eur J Pediatr       Date:  2010-01-26       Impact factor: 3.183

Review 3.  The Prenatal Origin of Childhood Leukemia: Potential Applications for Epidemiology and Newborn Screening.

Authors:  Erin L Marcotte; Logan G Spector; Daniela P Mendes-de-Almeida; Heather H Nelson
Journal:  Front Pediatr       Date:  2021-04-23       Impact factor: 3.418

4.  Why Who Marries Whom Matters: Effects of Educational Assortative Mating on Infant Health in the U.S. 1969-1994.

Authors:  Emily Rauscher
Journal:  Soc Forces       Date:  2019-05-24

5.  A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL).

Authors:  Elva Jiménez-Hernández; Arturo Fajardo-Gutiérrez; Juan Carlos Núñez-Enriquez; Jorge Alfonso Martín-Trejo; Laura Eugenia Espinoza-Hernández; Janet Flores-Lujano; José Arellano-Galindo; Aurora Medina-Sanson; Rogelio Paredes-Aguilera; Laura Elizabeth Merino-Pasaye; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; Rosa Martha Espinosa-Elizondo; Raquel Amador-Sánchez; Juan José Dosta-Herrera; Javier Anastacio Mondragón-García; Heriberto Valdés-Guzmán; Laura Mejía-Pérez; Gilberto Espinoza-Anrubio; María Minerva Paz-Bribiesca; Perla Salcedo-Lozada; Rodolfo Ángel Landa-García; Rosario Ramírez-Colorado; Luis Hernández-Mora; María Luisa Pérez-Saldivar; Marlene Santamaría-Ascencio; Anselmo López-Loyola; Arturo Hermilo Godoy-Esquivel; Luis Ramiro García-López; Alison Ireri Anguiano-Ávalos; Karina Mora-Rico; Alejandro Castañeda-Echevarría; Roberto Rodríguez-Jiménez; José Alberto Cibrian-Cruz; Karina Anastacia Solís-Labastida; Rocío Cárdenas-Cardos; Armando Martínez-Avalos; Luz Victoria Flores-Villegas; José Gabriel Peñaloza-González; Ana Itamar González-Ávila; Martha Beatriz Altamirano-García; Norma López-Santiago; Martin Sánchez-Ruiz; Roberto Rivera-Luna; Luis Rodolfo Rodríguez-Villalobos; Francisco Hernández-Pérez; Jaime Ángel Olvera-Durán; Luis Rey García-Cortés; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Cesar Raúl González-Bonilla; Vilma Carolina Bekker-Méndez; Silvia Jiménez-Morales; Haydee Rosas-Vargas; Juan Manuel Mejía-Aranguré
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

6.  The Association Between High Birth Weight and Long-Term Outcomes-Implications for Assisted Reproductive Technologies: A Systematic Review and Meta-Analysis.

Authors:  Åsa Magnusson; Hannele Laivuori; Anne Loft; Nan B Oldereid; Anja Pinborg; Max Petzold; Liv Bente Romundstad; Viveca Söderström-Anttila; Christina Bergh
Journal:  Front Pediatr       Date:  2021-06-23       Impact factor: 3.418

7.  Birth Weight and Risk of Childhood Acute Lymphoblastic Leukemia in Arizona, Illinois, and Kentucky.

Authors:  Frank D Groves; Brittany T Watkins; Daniel J Roberts; Thomas C Tucker; Tiefu Shen; Timothy J Flood
Journal:  South Med J       Date:  2018-10       Impact factor: 0.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.